Who are Lenalidomide-Dexamethasone-DLI's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lenalidomide-dexamethasone-dli.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Lenalidomide-Dexamethasone-DLI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lenalidomide-Dexamethasone-DLI (Lenalidomide-Dexamethasone-DLI) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulatory drug and corticosteroid. Area: Oncology.

phase 2 Immunomodulatory drug and corticosteroid Ubiquitin-proteasome pathway Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Lenalidomide-Dexamethasone-DLI (Lenalidomide-Dexamethasone-DLI) — Ciusss de L'Est de l'Île de Montréal. Lenalidomide is an immunomodulatory drug that targets the ubiquitin-proteasome pathway, and Dexamethasone is a corticosteroid that modulates the immune response. DLI (Donor Lymphocyte Infusion) is a form of immunotherapy that involves infusing donor lymphocytes to treat hematologic malignancies.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lenalidomide-Dexamethasone-DLI TARGET	Lenalidomide-Dexamethasone-DLI	Ciusss de L'Est de l'Île de Montréal	phase 2	Immunomodulatory drug and corticosteroid	Ubiquitin-proteasome pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulatory drug and corticosteroid class)

Ciusss de L'Est de l'Île de Montréal · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lenalidomide-Dexamethasone-DLI — Competitive Intelligence Brief. https://druglandscape.com/ci/lenalidomide-dexamethasone-dli. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing